Drug Trial Radar · NCT00829829
PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Last checked: Nov 20, 2026Latest source record: Apr 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
241
Actual
Start
Feb 2009
Primary completion
May 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.
Conditions
- Intercritical Gout
Interventions
PlaceboOther
Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
Rilonacept 80 mgDrug
Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
Rilonacept 160 mgDrug
Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)Time frame: Day 1 to Day 112 (Week 16)
Locations
91 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Gilbert, Arizona
Site not named
Peoria, Arizona
Site not named
Searcy, Arkansas
Site not named
Concord, California
Site not named
San Diego, California
Site not named
Santa Maria, California
Site not named
Trumball, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Daytona Beach, Florida
Site not named
Delray Beach, Florida
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Naples, Florida
Site not named
St. Petersburg, Florida
Site not named
Gainsville, Georgia
Site not named
Rome, Georgia
Site not named
Tucker, Georgia
Site not named
Woodstock, Georgia
Site not named
Boise, Idaho
Site not named
Avon, Indiana
Site not named
Evansville, Indiana
Site not named
South Bend, Indiana
Site not named
Wichita, Kansas
Site not named
Bowling Green, Kentucky
Site not named
Owensboro, Kentucky
Site not named
Baltimore, Maryland
Site not named
Ellicott City, Maryland
Site not named
Resistertown, Maryland
Site not named
Troy, Michigan
Site not named
Jackson, Mississippi
Site not named
Florissant, Missouri
Site not named
Las Vegas, Nevada
Site not named
Las Vegas, Nevada
Site not named
Berkeley Heights, New Jersey
Site not named
Freehold, New Jersey
Site not named
Brooklyn, New York
Site not named
Greensboro, North Carolina
Site not named
Hickory, North Carolina
Site not named
Morehead City, North Carolina
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.